Evercore ISI started coverage on shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) in a research note issued to investors on Wednesday. The brokerage set an “outperform” rating and a $154.00 price target on the biopharmaceutical company’s stock. Evercore ISI’s price objective suggests a potential upside of 49.70% from the stock’s current price.

Several other equities research analysts also recently issued reports on the company. Cantor Fitzgerald reiterated a “buy” rating and set a $208.00 price target on shares of GW Pharmaceuticals PLC in a report on Tuesday, May 9th. Maxim Group reiterated a “buy” rating and set a $135.00 price target on shares of GW Pharmaceuticals PLC in a report on Thursday, May 25th. Zacks Investment Research downgraded GW Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Monday, May 15th. BidaskClub upgraded GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Finally, ValuEngine upgraded GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Five equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $148.55.

Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) traded down 0.49% during mid-day trading on Wednesday, reaching $102.37. 71,532 shares of the company’s stock traded hands. The company’s market cap is $2.59 billion. GW Pharmaceuticals PLC has a 12 month low of $79.62 and a 12 month high of $137.88. The company has a 50 day moving average of $107.57 and a 200 day moving average of $113.04.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.73) by $0.34. GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. The company had revenue of $3.14 million for the quarter, compared to the consensus estimate of $2.10 million. During the same quarter last year, the company posted ($0.05) EPS. Analysts expect that GW Pharmaceuticals PLC will post ($6.19) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/08/16/gw-pharmaceuticals-plc-gwph-earns-outperform-rating-from-analysts-at-evercore-isi.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC purchased a new position in GW Pharmaceuticals PLC during the second quarter valued at $70,128,000. Capital World Investors increased its position in GW Pharmaceuticals PLC by 6.3% in the second quarter. Capital World Investors now owns 675,800 shares of the biopharmaceutical company’s stock valued at $67,749,000 after buying an additional 40,000 shares during the last quarter. Jennison Associates LLC increased its position in GW Pharmaceuticals PLC by 5.2% in the second quarter. Jennison Associates LLC now owns 490,721 shares of the biopharmaceutical company’s stock valued at $49,195,000 after buying an additional 24,376 shares during the last quarter. Redmile Group LLC increased its position in GW Pharmaceuticals PLC by 33.8% in the second quarter. Redmile Group LLC now owns 444,936 shares of the biopharmaceutical company’s stock valued at $44,605,000 after buying an additional 112,392 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in GW Pharmaceuticals PLC by 11.0% in the second quarter. Alliancebernstein L.P. now owns 317,956 shares of the biopharmaceutical company’s stock valued at $31,875,000 after buying an additional 31,481 shares during the last quarter. Institutional investors own 74.98% of the company’s stock.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.